-
公开(公告)号：US20230210860A1
公开(公告)日：2023-07-06
申请号：US17818294
申请日：2022-08-08
Applicant: Shionogi & Co., Ltd. , F. HOFFMANN-LA ROCHE AG
Inventor： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC: A61K31/5383 , A61K31/215 , A61P31/16
CPC classification number: A61K31/5383 , A61K31/215 , A61P31/16
Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
公开(公告)号：US20200330473A1
公开(公告)日：2020-10-22
申请号：US16830764
申请日：2020-03-26
Applicant: F. Hoffmann-La Roche AG , Shionogi & Co., Ltd.
Inventor： Takeshi NOSHI , Takahiro NODA , Ryu YOSHIDA , Takao SHISHIDO , Kaoru BABA , Aeron C. HURT , Leo Yi Yang LEE , Steffen WILDUM , Klaus KUHLBUSCH , Barry CLINCH , Michael J. NEBESKY , Annabelle LEMENUEL-DIOT , Wendy S. BARCLAY , Jean-Eric CHAROIN , Yoshinori ANDO
IPC: A61K31/5383
Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient. Therefore, one aspect of the present invention relates to a method for preventing an influenza epidemic or an influenza pandemic, wherein the method comprises administering an effective amount of a compound to patients having an influenza virus infection (index patients), wherein the compound is administered to at least 10% of all influenza infected persons of a city's or country's population, and wherein the compound has one of the formulae (I) and (II), or is a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220008429A2
公开(公告)日：2022-01-13
申请号：US16825263
申请日：2020-03-20
Applicant: Shionogi & Co., Ltd. , F. HOFFMANN-LA ROCHE AG
Inventor： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC: A61K31/5383 , A61K31/215 , A61P31/16
Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
公开(公告)号：US20240285643A1
公开(公告)日：2024-08-29
申请号：US18602656
申请日：2024-03-12
Applicant: Shionogi & Co., Ltd. , F. HOFFMANN-LA ROCHE AG
Inventor： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC: A61K31/5383 , A61K31/215 , A61P31/16
CPC classification number: A61K31/5383 , A61K31/215 , A61P31/16
Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
公开(公告)号：US20200297731A1
公开(公告)日：2020-09-24
申请号：US16825263
申请日：2020-03-20
Applicant: Shionogi & Co., Ltd. , F. HOFFMANN-LA ROCHE AG
Inventor： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC: A61K31/5383 , A61K31/215 , A61P31/16
Abstract: A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
6.发明申请
公开(公告)号：US20210228590A1
公开(公告)日：2021-07-29
申请号：US17204246
申请日：2021-03-17
Applicant: SHIONOGI & CO., LTD.
Inventor： Takao SHISHIDO , Keita FUKAO , Takeshi NOSHI , Yoshinori ANDO , Takahiro NODA
IPC: A61K31/5383 , A61P31/16 , A61K9/00 , A61K9/28 , A61K9/48 , A61K9/06 , A61K31/245 , A61K45/06 , A61K9/70
Abstract: A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.
-
7.发明公开
公开(公告)号：US20230233573A1
公开(公告)日：2023-07-27
申请号：US18192491
申请日：2023-03-29
Applicant: SHIONOGI & CO., LTD.
Inventor： Takao SHISHIDO , Keita FUKAO , Takeshi NOSHI , Yoshinori ANDO , Takahiro NODA
IPC: A61K31/5383 , A61P31/16 , A61K9/00 , A61K9/06 , A61K9/28 , A61K9/48 , A61K9/70 , A61K31/245 , A61K45/06
CPC classification number: A61K31/5383 , A61P31/16 , A61K9/0019 , A61K9/0053 , A61K9/0056 , A61K9/007 , A61K9/0095 , A61K9/06 , A61K9/282 , A61K9/2826 , A61K9/4858 , A61K9/7007 , A61K31/245 , A61K45/06
Abstract: A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.
-
公开(公告)号：US20220331331A1
公开(公告)日：2022-10-20
申请号：US17560501
申请日：2021-12-23
Applicant: Hoffmann-La Roche Inc. , Shionogi & Co., Ltd.
Inventor： Takeshi NOSHI , Takahiro NODA , Ryu YOSHIDA , Takao SHISHIDO , Kaoru BABA , Aeron C. HURT , Leo Yi Yang LEE , Steffen WILDUM , Klaus KUHLBUSCH , Barry CLINCH , Jan Michal NEBESKY , Annabelle LEMENUEL , Wendy S. BARCLAY , Jean-Eric CHAROIN , Yoshinori ANDO
IPC: A61K31/5383
Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient. Therefore, one aspect of the present invention relates to a method for preventing an influenza epidemic or an influenza pandemic, wherein the method comprises administering an effective amount of a compound to patients having an influenza virus infection (index patients), wherein the compound is administered to at least 10% of all influenza infected persons of a city's or country's population, and wherein the compound has one of the formulae (I) and (II), or is a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20200261481A1
公开(公告)日：2020-08-20
申请号：US16061495
申请日：2016-12-14
Applicant: Shionogi & Co., Ltd.
Inventor： Takao SHISHIDO , Takeshi NOSHI , Atsuko YAMAMOTO , Mitsutaka KITANO
IPC: A61K31/685 , A61K31/426 , A61K31/5383 , A61K31/53 , A61K39/395 , A61K45/06 , A61K31/664 , A61P31/16 , A61K31/196 , A61K31/351 , A61K31/506
Abstract: A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4 is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A are each independently hydrogen, halogen, alkyl, or the like; R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R1 is or the like, is combined with (B) compound(s) having an anti-influenza activity, its pharmaceutically acceptable salt or a solvate thereof and/or an antibody having anti-influenza activity, is useful for treating or preventing influenza.
